title: Protective effect of co-administration of rosuvastatin and probucol on atherosclerosis in rats.
abstract: This study aimed to study the combined effect of rosuvastatin and probucol on atherosclerosis (AS) in rats. In total, 95 male Wistar rats were divided into 5 groups: 25 in the control group (A), 25 in the model group (B), 15 in the rosuvastatin group (C), 15 in the probucol group (D), and 15 in the rosuvastatin combined probucol group (E). A high-lipid diet and vitamin D3 were administered to establish AS rat model. Groups C, D, and E received corresponding drugs. Blood lipids, oxidized low-density lipoprotein (OX-LDL), malonaldehyde (MDA), superoxide dismutase (SOD), adiponectin (APN), and vascular endothelial cadherin (VE-cadherin) were measured. Platelet endothelial cell adhesion molecule-1 (PECAM-1) was detected by immune histochemistry. In groups B-E, AS rat models were successfully constructed. In groups C-E, blood lipids, OX-LDL, VE-cadherin, MDA, PECAM-1, and intimal thickness were decreased (p < 0.01), while SOD and APN were increased (p < 0.05), compared with that in group B. Furthermore, group E had lower levels of OX-LDL, MDA, and PECAM-1 but higher levels of SOD and APN and attenuated intimal thickening compared with groups C or D (p < 0.05). Administering rosuvastatin and probucol could attenuate AS lesions through modulation of oxidative stress, PECAM-1, and APN. Both drugs might help slow the progression of AS.
authors.affiliation: a Department of Cardiology, the Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao 266003, Shandong, People's Republic of China.
authors.forename: Zuoyuan
authors.initials: Z
authors.lastname: Chen
authors.forename: Shan
authors.initials: S
authors.lastname: Li
authors.forename: Wenna
authors.initials: W
authors.lastname: Zhao
authors.forename: Xiuhua
authors.initials: X
authors.lastname: Chen
authors.forename: Xiaxia
authors.initials: X
authors.lastname: Wang
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004359:Drug Therapy, Combination; D005464:Fluorobenzenes / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011341:Probucol / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D017208:Rats, Wistar; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology
chemical_list: D000975:Antioxidants; D005464:Fluorobenzenes; D008055:Lipids; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D011341:Probucol
keywords: adiponectin; adiponectine; blood lipids; immunohistochemistry; immunohistochimie; inflammation; lipides sanguins; oxidative stress; stress oxydant